Lancet oncol: EZH2 inhibitor, promising to be a new option for patients with folytic lymphoma!

The activation mutation of the e glygenetic regulatory gene EZH2 is found in about 20% of fage lymphomas.
study aims to study the activity and safety of the first-line oral EZH2 inhibitor tazemetostat for filthy lymphoma.
The study was an open-label, one-arm Phase 2 trial conducted in 38 hospitals or clinics in several countries, recruiting patients over the age of 18 with histologically diagnosed, recurring/refractic filamentatic lymphoma (1/2/3a or 3b).
patients into mutant (EZH2 mut) or wild (EZH2 WT) in EZH2 state.
to be treated orthostat 800 mg (2/day) or so.
end point of the problem is the objective mitigation rate.
July 9, 2015 - May 24, 2019, 99 patients were recruited: 45 EZH2 mutants and 54 EZH2 wild.
As of August 9, 2019, the EZH2 mutation group and the EZH2 wild group had a medium follow-up of 22.0 months and 35.9 months, respectively, with objective mitigation rates of 69% and 35%, with a medium remission duration of 10.9 months and 13.months, respectively, and a medium progress-free survival period of 13.8 months and 11.1 months, respectively.
adverse reactions associated with treatment level 3 and above were plate plate plate reduction (3%), neutral granulocyte reduction (3%) and anemia (2%).
adverse reactions associated with severe treatment were found in 4 patients (4%).
treatment-related deaths.
in general, tazemetostat monotherapy exhibits significant, long-lasting efficacy and good tolerance in recurring/refractive folytic lymphoma.
is expected to be a new option for patients with fable lymphoma.
.